Will we continue down this path, and if so, why? I suspect the NASDAQ-listed shares of Centennial Resource Development, Inc. might provide a clue to the answer. As of today, there have been no new developments with regards to the company, but it continues to fall consistently as Aethlon Medical, Inc. (Nasdaq: AEMD) shares drowned 6.73% to 2.08 in the premarket session.
And all this shows me is that investors are all quite shaken up by Aethlon Medical, Inc. (Nasdaq: AEMD) news on December 16, 2020, that the first patient was treated in the Company’s first clinical Early Feasibility Trial testing HEMOPURIFIER in patients with chronic and/or metastatic head and neck squamous cell carcinoma.
The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. Hemopurifier Plus Pembrolizumab in Head and Neck Cancer. I wondered whether all the anxiety was overblown.